Objective Bariatric surgery is an effective treatment for type 2 diabetes (T2D) that changes gut microbial composition. We determined whether the gut microbiota in humans after restrictive or malabsorptive bariatric surgery was sufficient to lower blood glucose.
Design Women with obesity and T2D had biliopancreatic diversion with duodenal switch (BPD-DS) or laparoscopic sleeve gastrectomy (LSG). Faecal samples from the same patient before and after each surgery were used to colonise rodents, and determinants of blood glucose control were assessed.
Results Glucose tolerance was improved in germ-free mice orally colonised for 7 weeks with human microbiota after either BPD-DS or LSG, whereas food intake, fat mass, insulin resistance, secretion and clearance were unchanged. Mice colonised with microbiota post-BPD-DS had lower villus height/width and crypt depth in the distal jejunum and lower intestinal glucose absorption. Inhibition of sodium-glucose cotransporter (Sglt)1 abrogated microbiota-transmissible improvements in blood glucose control in mice. In specific pathogen-free (SPF) rats, intrajejunal colonisation for 4 weeks with microbiota post-BPD-DS was sufficient to improve blood glucose control, which was negated after intrajejunal Sglt-1 inhibition. Higher Parabacteroides and lower Blautia coincided with improvements in blood glucose control after colonisation with human bacteria post-BPD-DS and LSG.
Conclusion Exposure of rodents to human gut microbiota after restrictive or malabsorptive bariatric surgery improves glycaemic control. The gut microbiota after bariatric surgery is a standalone factor that alters upper gut intestinal morphology and lowers Sglt1-mediated intestinal glucose absorption, which improves blood glucose control independently from changes in obesity, insulin or insulin resistance.
- glucose metabolism
- obesity surgery
- intestinal microbiology
- diabetes mellitus
- intestinal absorption
Data availability statement
Data are available on reasonable request.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
WHAT IS ALREADY KNOWN ON THIS TOPIC?
Bariatric surgery is the most effective long-term treatment for type 2 diabetes (T2D).
Bariatric surgery lowers blood glucose before weight loss.
Blood glucose lowering is greater after malabsorptive compared with restrictive bariatric surgery.
Bariatric surgery changes the composition of the gut microbiota.
Gut microbiota can influence obesity and blood glucose.
It was not known if altered gut microbiota after bariatric surgery in humans is a standalone factor that lowers blood glucose.
WHAT THIS STUDY ADDS?
Microorganisms from humans after malabsorptive and restrictive bariatric surgery are sufficient to improve blood glucose control in mice.
Microbiota -mediated transmission of lower blood glucose required long-term (7 weeks) colonisation of germ-free mice by oral gavage and SPF rats (4 weeks) by intraluminal delivery.
Microbiota -mediated transmission of improved glucose control does not require changes in fat mass, insulin resistance, secretion, or clearance.
Microbiota lowering of blood glucose was due to lower sodium-dependent intestinal glucose absorption.
A subset of bacteria after bariatric surgery coincided with altered gut morphology and lower intestinal glucose absorption in mice.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY?
Microbiota in humans after bariatric surgery is sufficient to lower intestinal glucose absorption and blood glucose.
Development of probiotics or postbiotics that mimic the microbial effect of bariatric surgery and lower intestinal glucose absorption may promote durable blood glucose -lowering benefits in T2D without the drawbacks of bariatric surgery.
Obesity predicts the progression to type 2 diabetes (T2D), which is characterised by elevated blood glucose, glucose intolerance and insulin resistance.1 2 Bariatric surgery promotes durable weight loss and is more effective than conventional medical interventions for long-term control of T2D.3 Higher blood glucose is an independent risk factor for all-cause mortality, and bariatric surgery can increase survival in individuals with obesity.4 5 Bariatric surgery rapidly lowers blood glucose and insulin resistance before any measurable weight loss.6 7 However, it is still unclear how bariatric surgery promotes rapid versus durable blood glucose lowering facilitating T2D remission.
Laparoscopic sleeve gastrectomy (LSG) and biliopancreatic diversion with duodenal Switch (BPD-DS) span the spectrum of bariatric surgeries. LSG is a restrictive surgery that reduces the size of the stomach. BPD-DS is a malabsorptive and restrictive surgery because it creates a stomach pouch in addition to a long by-pass of the small intestine.7 Compared with LSG, BPD-DS produces a more robust and sustained lowering of blood glucose, including greater T2D remission, which comes at the cost of more frequent side effects.7 8
Bariatric surgeries alter the composition and function of the intestinal microbiota.6 7 Conserved shifts in gut microbiota after gastric bypass surgery in humans can promote weight loss and fat loss when transferred to germ-free mice.9 There is evidence for a causal role for gut microbes in lowering fat mass after bariatric surgery in some preclinical models.9–11 It is known that gut microbes influence host metabolism and can contribute to features of the metabolic syndrome beyond obesity, including insulin resistance and glycaemic control.12 13 There is a dearth of information on a causal role for gut microorganisms after bariatric surgery as a standalone factor lowering blood glucose.6 14
Here, we colonised mice and rats with the faecal microbiota from the same patients before and after LSG or BPD-DS to test the causal relationship between gut microorganisms and blood glucose lowering by bariatric surgery and define the mechanisms of blood glucose lowering by the gut microbiota.
Materials and methods
Female C57BL6/N mice aged 16−24 weeks were originally sourced from Taconic and bred in the Central Animal Facility (CAF), McMaster University, under specific pathogen-free (SPF) or germ-free (GF) conditions. Mice received diet (Teklad global 18% protein rodent diet, Envigo, Cat# 2918) and water ad libitum. Female Sprague-Dawley rats aged 10 weeks (Charles River Laboratories) were housed in individual cages in a SPF room under a standard 12 hours light-dark cycle with ad libitum access to drinking water and chow (Teklad Diet 7012, Harlan Laboratories, Madison, Wisconsin, USA).
Patients were enrolled in the Bariatric Surgery Care Centre of the Québec Heart and Lung Institute according to institutionally approved procedures. A detailed description of bariatric surgical procedures is in the online supplemental material.
Patient and public involvement
Many participants have been invited to attend a presentation held by clinicians and researchers in the context of the patient support group meetings. Two participants have shared their experience in videos.
Donor patients and faecal slurries
We selected three female patients with typical changes in body mass and glycaemic characteristics 12 months postsurgery (table 1). Stool samples, from the same patient were collected before and 12 months after BPD-DS or LSG, frozen immediately at −20°C and subsequently stored at −80°C. Faeces were later thawed on ice, resuspended in phosphate-buffered saline (1:10 (w:v)), aliquoted in 1.5 mL tubes and stored at −80°C until use. None of these patients took antibiotics at least 1 month before each faecal collection. Medication use and caloric intake are indicated in online supplemental tables 1 and 2.
Human-to-mouse faecal transplants
GF mice were exported from the axenic facility to the SPF room in closed sterile containers, which were opened under a disinfected biosafety cabinet (BSC). Freshly thawed faecal slurries from donor patients were orally gavaged into randomly assigned SPF (200 µL/mouse/3 times a week) and GF (200 µL/mouse/2 times a week) mice for a total of 9 weeks. Faecal slurries from one donor patient were used to colonise two to five mice, and separate mice were used for testing the faeces from the same patient before and after surgery. After the initial colonisation, GF mice were transferred (single-housed) to sterile cages with access to sterile water, which were refreshed weekly. SPF mice were kept four mice per cage with water and cage refreshed weekly. Handling of colonised GF mice was performed under a BSC. All mice were kept in ventilated cages in positive pressure mode.
Intestinal glucose absorption
In vivo intestinal glucose absorption was measured after 6 hours fasting in GF mice colonised with the gut microbiota from BPD-DS patients for 7 weeks. A non-metabolisable glucose analogue (3-O-methyl-D-glucopyranose (3-OMG), 4 mg/mouse) and paracetamol (1 mg/mouse) were gavaged to mice and quantified in circulation by high-pressure liquid chromatography equipped with a triple quadrupole mass spectrometer (see online supplemental material for further details).
Intestinal and vascular surgery
Rats were anaesthetised (ketamine, 60 mg/kg; xylazine, 8 mg/kg) prior to surgical procedures. Gut catheters were placed into the luminal compartment 6 cm and 18–22 cm distal to the pyloric sphincter and therefore positioned at the upper small intestine (USI) and middle jejunum, respectively. Alternatively, the middle jejunum catheters were replaced by more distal cannulation placed at the middle ileum (see online supplemental methods for details). For vascular surgery, catheters were implanted into the left carotid artery and right jugular vein for blood sampling. Postsurgical food intake and body weight were monitored daily for 5 days leading up to the experiment. Rats that did not attain at least 85% of their pre-USI/jejunal and vascular surgical body weight were excluded.
Human-to-rat faecal transplants and upper small intestine glucose tolerance test
Equivalent amounts of stool samples from BPD-DS donor patients were pooled together for each timepoint (ie, presurgery and postsurgery). Faecal slurries were obtained from combined stools before and after surgery as described in Donor patients and faecal slurries. One day following jejunal cannulation, freshly thawed slurries were directly infused into the jejunal cannula to target the distal jejunum and ileum of SPF rats (1.5 mL/rat, 3 times/week for 4 weeks). On 3 weeks of colonisation, rats underwent surgery for USI and vascular cannulation. After 5 days of recovery (during which colonisation via jejunal cannula was maintained), rats were fasted overnight (16 hours, from 16:00 to 8:00 hours), and a bolus of phloridzin (P3449, Sigma-Aldrich, 0.04 g/kg) or vehicle (10% dimethyl sulfoxide and 10% ethanol in 0.9% saline) was infused via jejunal cannula (targeting distal jejunum and ileum) and was immediately followed by a bolus of glucose (G8769, Sigma-Aldrich, 4 g/kg) infusion into the USI cannula (targeting almost the entire small intestine). Blood glucose was monitored 0, 5, 10, 20, 30, 40 min after USI glucose infusion.
See online supplemental methods for details on metabolic phenotyping, bacterial profiling, histological analysis, messenger RNA (mRNA) extraction, RT-PCR analysis, immunoblotting and short-chain fatty acid determination.
Analysis of microbial populations was conducted in R. Partitioning of the variance in the microbiota was done with a permutational multivariate analysis of variance on Bray-Curtis dissimilarities calculated from relative amplicon sequence variant (ASV) abundances. The Wilcoxon rank-sum test was used for pairwise comparisons. Adjustment for the false discovery rate was calculated with the Benjamini-Hochberg method.15 R packages used for data analysis and visualisation included phyloseq,16 vegan,17 UpsetR,18 ggplot2,19 tidyr,20 dplyr,21 ggtree22 and corrplot.23 Significance was accepted at p<0.05. Statistical analyses of other variables were done using unpaired two-tailed Student’s t-test in GraphPad Prism V.9.
Data availability: all data and R scripts generated in this study are available on reasonable request. 16S rRNA gene sequencing data were deposited to the National Institutes of Health’s Sequence Read Archive (temporary ID 124400).
Gut microbiota after bariatric surgery improves blood glucose control
Female patients had lower fasting blood glucose 12 months after LSG or BPD-DS (figure 1A, table 1). Faecal slurries from one donor patient before (presurgery) or 12 months after (postsurgery) each type of bariatric surgery were used to colonise two to five mice, and separate mice were used for testing the faeces from the same patient before and after surgery (figure 1B). GF mice, but not their SPF counterparts, had lower blood glucose and lower area under the curve (AUC) during a glucose tolerance test (GTT) following long-term (7 weeks) exposure to faecal samples from patients post-BPD-DS as compared with mice exposed for the same amount of time to patient faecal slurries before BPD-DS (figure 1C,D). We observed similar outcomes when faecal samples from LSG patients were used to colonise mice for 7 weeks, where lower blood glucose tolerance and lower AUC during a GTT was observed for GF, but not SPF mice, which received faeces from patients post-LSG as compared with mice exposed to patient faecal matter before LSG (figure 1E,F). This microbiota-transmissible improvement in glucose tolerance using faecal material after BPD-DS and LSG was not associated with changes in food intake or body composition in GF mice (online supplemental figure 1). We found that human-to-mouse faecal microbiota transmission of improved glucose tolerance postbariatric surgery was not attributable to a specific human patient (figure 1D,F—see in the legend at the top the p values for within-donor comparison of AUC during a GTT in mice). These data show that bariatric surgery-induced changes in the human microbiota within the same patient can transmit improved glucose tolerance to GF mice without changes in food intake or fat mass.
Gut microbiota after bariatric surgery lowers intestinal glucose absorption
To gain mechanistic insight into gut microbiota-mediated human-to-mouse transmission of improved glucose control, we first assessed glucose-stimulated insulin/c-peptide secretion (GSIS) and insulin sensitivity in GF mice colonised with faeces before and after BPD-DS (figure 2A). Pre-BPD-DS and post-BPD-DS colonised mice had similar plasma insulin and c-peptide levels during GSIS (figure 2B–E) and similar insulin clearance, as measured by insulin/c-peptide ratio (figure 2F,G). Furthermore, pre-BPD-DS and post-BPD-DS recipient mice showed similar indices of insulin resistance, as measured by insulin resistance index (during the GTT) and homeostasis model assessment-estimated insulin resistance (figure 2H,I). Likewise, GF mice colonised with the microbiota before or after BPD-DS showed comparable blood glucose and glucose disappearance rate during an insulin tolerance test (figure 2J,K). No differences were found in SPF mice that received the faecal microbiota pre-BPD-DS or post-BPD-DS (online supplemental figure 2). These data show that improved glucose control in GF colonised with microbes after BPD-DS is not associated with changes in insulin secretion, clearance or sensitivity.
Previous studies have documented changes in intestinal glucose absorption associated with improved glycaemic homeostasis in Roux-en-Y Gastric Bypass (RYGB) and LSG.24–28 However, it was unknown if bariatric surgery-induced changes in glucose absorption are linked to changes in the gut microbiota. We hypothesised that lower blood glucose during an oral glucose load in GF mice colonised with the microbiota from patients after BPD-DS was due to lower intestinal glucose absorption. We gavaged another cohort of GF mice colonised with the microbiota of BPD-DS patients before and after surgery with a non-metabolisable glucose analogue (3-OMG), to assess gut glucose absorption, and paracetamol, to assess gastric emptying (figure 3A). Consistent with lower intestinal glucose absorption, GF mice colonised with the microbiota after BPD-DS had lower rate of appearance of 3-OMG in circulation and lower peak 3-OMG serum concentration compared with mice colonised with presurgery microbes (figure 3B,C). GF mice colonised with either presurgery or postsurgery microbes had no change in gastric emptying indicated by a similar rate of appearance and peak levels of paracetamol in the serum (figure 3D,E).
The sodium-glucose cotransporter (Sglt)1 is the main glucose carrier from the lumen to the enterocyte. We next pharmacologically inhibited Sglt1 in mice colonised with gut microbes pre-LSG or post-LSG (figure 4A). We first performed oral GTT in naïve SPF mice to determine a dose of phloridzin that attenuated (but not eliminated) gut glucose absorption (online supplemental figure 3A–E). We showed that 0.04 g phloridzin/kg significantly lowered glucose entry through the gut during an oral glucose load, but not blood glucose clearance, since vehicle-treated and phloridzin-treated mice displayed comparable glucose tolerance on intraperitoneal GTT (online supplemental figure 3F, G). We then colonised an additional cohort of GF mice with faecal slurries pre-LSG or post-LSG and performed an oral GTT 1 hour after administration of vehicle or phloridzin. We confirmed that weight-matched vehicle-treated mice colonised with faecal slurries post-LSG had lower blood glucose than pre-LSG colonised mice (figure 4B,C and figure 1F); however, on Sglt1 inhibition, this difference was eliminated (figure 4D,E). These data show that Sglt1-mediated intestinal glucose absorption is a determinant of the glucose-lowering effect of gut microorganisms post-LSG.
Gut microbiota post-BPD-DS alters gut morphology in recipient mice
We found no changes in Slc5a1 (Sglt1), neither in Slc2a1 (Glut1) and Slc2a2 (Glut2), mRNA expression in the proximal and distal small intestine of GF mice colonised with gut microbes pre-BPD-DS or post-BPD-DS and LSG (online supplemental figure 4). Surprisingly, morphological analysis revealed that GF mice colonised with the microbiota after BPD-DS had lower villus height, villus width and crypt depth in the distal small intestine (figure 5A,B), but not in the proximal small intestine (online supplemental figure 5), as compared with GF mice that were colonised with the pre-BPD-DS microbiota.
Gut microbiota post-BPD-DS relays signals to the host via Wnt/β-catenin pathway
We next sought to determine possible mechanisms mediating lower villus height, villus width and crypt depth observed in the distal small intestine of GF mice harbouring gut microorganisms pre-BPD-DS or post-BPD-DS. Short-chain fatty acids (SCFAs) are key bacterial products involved in host physiological control, including enterocyte homeostasis. While BPD-DS donors had higher levels of faecal butyric acid and LSG donors displayed lower levels of faecal acetic acid postsurgery, these features were not recapitulated in caecal contents of colonised mice (online supplemental figure 6), suggesting that SCFA are not the main players in the changes in gut structure, intestinal absorption or blood glucose in mice.
The Wnt/β-catenin pathway is known to integrate signals to control enterocyte proliferation through activation of β-catenin (online supplemental figure 7A). The levels of active/inactive β-catenin were lower in the distal small intestine of mice colonised with slurries post-BPD-DS comparable in the distal small intestine of GF mice pre-BPD-DS (online supplemental figure 7B–E), but mice with microorganisms post-BPD-DS showed higher levels of inactive β-catenin than counterparts harbouring the microbiota pre-BPD-DS (online supplemental figure 7B). These findings suggest that the gut microbiota after BPD-DS can relay signals to the host and alter the activation status of β-catenin, which can potentially curb cell proliferation and possibly contribute to lower gut absorptive surface in intestinal cells exposed to the microbiota after bariatric surgery.
Targeted colonisation of the distal small intestine with the gut microbiota from patients post-BPD-DS lowers blood glucose in rats in a Sglt1-dependent manner
To test gut microbial-related changes directly in the distal small intestine in another model that already harbours a microbiota, we colonised female SPF rats by directly infusing faecal slurries from female patients before or after BPD-DS into the rat’s distal small intestine followed by USI GTT (figure 6A). In weight-matched SPF rats (figure 6B), distal small intestinal colonisation with the gut microbiota from patients after BPD-DS was sufficient to lower blood glucose AUCs on USI-GTT compared with rats that received the faecal slurries pre-BPD-DS (figure 6C). With comparable pre-experimental body mass (figure 6D), this effect was negated by intrajejunal administration of phloridzin (figure 6E). To assess whether the distal small intestinal glucose absorption occurs in the ileum, glucose was infused into the ileum, instead of USI, of rats via ileal cannulation. We found that ileal glucose infusion failed to elevate blood glucose (online supplemental figure 8). These data suggest that gut microbes after BPD-DS can improve glucose tolerance in the host by locally reducing glucose absorption in the distal jejunum, but not the ileum, of SPF rats.
Specific taxonomic features in recipient mice post-BPD-DS and post-LSG are linked to microbiota-transmissible improvements in blood glucose control
To identify bacterial community characteristics transmitted from bariatric surgery patients to mice, we applied 16S rRNA gene-based sequencing analysis of faecal samples of GF colonised with the microbiota before and after LSG and BPD-DS. In our model, 7.3% and 18.7% of the ASVs identified in the stools of donor patients who underwent BPD-DS and LSG, respectively, were transmitted to recipient GF mice (online supplemental figure 9). The transmitted taxa represented 13.1% and 20% of all ASVs found in the BPD-DS and LSG recipient mice, respectively (online supplemental figure 9). Consistent with previous reports,29 30 BPD-DS tended to lower α-diversity in donor patients (online supplemental figure 10A), which was not seen after LSG (online supplemental figure 10B). We found that α-diversity was not different in GF mice colonised with human faeces from BPD-DS and LSG patients (online supplemental figure 10C,D), indicating that microbial α-diversity in stool samples is not a key feature in human to mouse microbiota-mediated transmission of changes in blood glucose. These findings are in agreement with reports showing that improved glycaemic control postbariatric surgery is not associated with higher bacterial diversity.30 31
Principal component analysis of Bray-Curtis dissimilarity of the taxonomic composition of stool samples from mice colonised with faeces from BPD-DS or LSG patients showed no separation in the microbial community composition pre-BPD-DS and post-BPD-DS (figure 7A). Conversely, the microbial composition of the stool samples segregated pre-LSG and post-LSG, with 46.2% of the variation among samples explained by the first two axes (figure 7B). We further investigated abundance of taxa presurgery and post-surgery and found that post-LSG recipient stools had higher levels of Parabacteroides and several members of the class Clostridia (eg, Caproiciproducens, Robinsoniella, GCA-900066575) compared with pre-LSG recipients (figure 7C and online supplemental figure 11). Blautia, another member of the class Clostridia, was an exception and showed lower abundance in post-LSG recipients (figure 7C and online supplemental figure 11). For the BPD-DS recipients, we found a more subtle expansion of Clostridia characterised by higher presence of three taxa: Robinsoniella, GCA-900066575 (which were also higher in post-LSG recipients) and Anaerostignum (figure 7C and online supplemental figure 11). Similar to GF mice that were colonised with the microbiota after LSG, lower Blautia and elevated levels of Parabacteroides was also found in GF mice colonised with post-BPD-DS microbiota (figure 7C and online supplemental figure 11). Our findings highlight taxonomic features post-BPD-DS and post-LSG linked to microbiota-transmissible improvements in blood glucose control.
Our data show that a subset of gut microorganisms from patients after two different bariatric surgeries is associated with better glucose tolerance independently of changes in fat mass in mice. We found that the gut microbiota after restrictive and malabsorptive surgery in humans contain microbes (or microbial factors) that can lower blood glucose. However, we found that the microbiota after either bariatric surgery did not change insulin secretion, insulin clearance or insulin resistance. We found that the mechanism for lower blood glucose caused by the microbiota after bariatric surgery was a lower intestinal glucose absorption in the distal small intestine. This is important because patients with morbid obesity have increased intestinal glucose absorption.32 It was already known that bariatric surgery, such as BPD-DS, promotes glucose excretion into the gut lumen28 and increases enterocyte hyperplasia/hypertrophy and glycolysis, rendering the intestine a key site for blood glucose disposal.25–27 33 However, while these adaptive changes typical of malabsorptive surgery are not present in LSG patients, lower intestinal glucose absorption is still seen following restrictive procedures.26 27 Here, we show that bacteria after bariatric surgery are a standalone factor that can lower the host’s enteric absorptive surface, and lower postprandial glucose absorption in the gut. There is a precedent for gut microorganisms and diet regulating intestinal morphology. Probiotic bacteria can modify intestinal morphology in fish,34 and high fat-fed mice have lower gut absorptive surface.35 It is enticing to speculate that certain gut microorganisms after bariatric surgery in humans, may exert counter-regulatory pressure as a means to compensate for enterocyte hyperplasia/hypertrophy after malabsorptive surgery,25 which, in light of our findings, may engage the Wnt/β-catenin pathway to relay signals to the host upper intestine.
The microbiota composition rapidly changes after bariatric surgery.6 We initially hypothesised that changes in microbes would participate in blood glucose lowering early after bariatric surgery, such as the first few days before significant weight loss. However, our data raise the intriguing possibility that the function of microbes may be to improve long-term blood glucose control rather than the immediate effects of bariatric surgery. In our study, we used germ-free mice colonised for at least 7 weeks since sufficient exposure time (ie, >45 days) and multiple instillations by gavage are required for microorganisms to influence blood glucose in GF mice.36 37 Modest improvements in glucose homeostasis after faecal microbial transplants into mice from rats that underwent RYGB have been reported after short periods of time.14 While this can be in part explained by differences in human BPD-DS compared with rat RYGB,8 exposure time of the host to certain microbes appears to be a key factor in altering blood glucose.
In our hands, colonisation via oral gavage of SPF mice with gut microbiota before and after bariatric surgery failed to transmit better glucose tolerance. However, we discovered that long-term (3 times/week for 4 weeks) direct intraluminal microbial transplantation into the distal small intestine of SPF rats can circumvent this limitation and transmit lower blood glucose using faecal bacteria after bariatric surgery. These findings set the stage to enhance microbial transplant protocols that can alter host metabolism. Overall, our work positions microbiota-induced changes in intestinal morphology and glucose absorption as a factor that could contribute to durable lowering of blood glucose and long-term T2D remission.
Amplicon-based methods, like the one used herein, do not allow an in-depth appreciation of colonisation efficiency, nor strain-level resolution of microbiota engraftment. Limitations considered, colonisation efficiency in our model was estimated to vary between 7% and 20%, which is lower than previously reported.12 37 We acknowledge that only a fraction of the donor microbiota is expected to survive sample collection, preparation/storage (eg, freeze-and-thaw cycles, exposure to oxygen) and delivery in our colonisation model. But most importantly, we showed that a relatively small subset of bacteria coming from the gut microbiota after two different types of bariatric surgery was sufficient to lower blood glucose in different rodent models. It is important to consider that (i) the human inocula before and after surgery were from the same patient and were processed equally, (ii) microbiota-transmissible improved glucose tolerance was seen in multiple cohorts of GF mice and in SPF rats and (iii) mouse and rat studies were performed by different operators in different animal facilities. While we could capitalise on this relatively small colonisation efficiency to narrow down the bacteria possibly implicated in lowering blood glucose in the host, it is important to acknowledge that our donor cohort was not big enough to allow a more precise identification of bacterial signatures in recipient mice. Each mouse was colonised with the faecal matter from one donor, and therefore the recipient mouse cohort reflected the high interindividual variability typically seen in the microbiota of human individuals. Importantly, we showed that transmission of improved glucose tolerance via microbiota transfer was not donor-specific, indicating that the diverse set of microbial communities that can occur in humans after different types of bariatric surgeries contain functional redundancies that can lower intestinal glucose absorption and blood glucose in the host.
Higher Parabacteroides and lower Blautia were among the key transmissible taxonomic features shared after restrictive and malabsorptive procedures and that coincided with better glucose control in recipient mice. We highlight these taxa because they were among the top 20 most abundant in the faeces of recipient mice and because previous findings have linked increased Parabacteroides spp with improved metabolic function during obesity.38 Our results agree with Ridaura et al, where the microbes in lean/normoglycaemic humans can override an obese phenotype in GF mice colonised with faecal material from twin pairs discordant for obesity. In particular, Bacteroides spp and Parabacteroides spp in lean-associated microbiota could colonise mice harbouring the microbiota associated with obesity.12 An alternative approach to using twin pairs is to use within-patient comparison before and after bariatric surgery as we have done here, where a robust reduction in body weight and blood glucose is observed (table 1). Our results expand this concept and show that microbiota transmissible alterations in host metabolism associated with Parabacteroides spp can lower blood glucose without lowering body mass. It is noteworthy that Parabacteroides spp and the closely related genus Bacteroides exhibit underacylated lipopolysaccharide (LPS) that can antagonise toll-like receptor 439–41 and polysaccharide A with tolerogenic potential,39 41 42 which may contribute to improved glucose tolerance in recipient mice postsurgery. Our data also point to Blautia as a common microbiota genus of improved blood glucose control postbariatric surgery. Indeed, Blautia was found to be higher in the faeces of individuals with diabetes43 44 and lower after bariatric surgery.6 29 Overall, our findings highlight that small groups of bacteria were consistently associated with transmission of improved blood glucose tolerance after two types of bariatric surgery. Since postbiotics can improve glucose homeostasis in the host,45–48 we believe our work provide foundational evidence to support research on postbiotics that can lower intestinal glucose absorption and blood glucose. As a perspective, it is enticing to explore the link between mucosal serotonin and the microbiota-related glucose-lowering effects of bariatric surgery in follow-up studies. Gut-derived serotonin secretion is a microbiota-influenced trait49 that has been shown to impact glucose regulation50 and gut morphology.51 In addition, while we showed that the human microbiota from women could transmit changes in blood glucose in female mice, any sex-dependent effect in males is not yet known.
We conclude that microorganisms in human faeces after bariatric surgery are a standalone factor that lowers Sglt1-mediated intestinal glucose absorption and consequently improves blood glucose control when transferred to rodents. This microbiota-driven effect is associated with structural changes in the villi of the distal small intestine. We propose a model where changes in microbiota contribute to the long-term glucose-lowering effects of bariatric surgery, independently of microbiota-related changes in obesity and insulin resistance. Microorganisms, and/or their components, that can lower glucose absorption should be mined as factors that can contribute to durable lowering of blood glucose by limiting entry of glucose into the host.
Data availability statement
Data are available on reasonable request.
Patient consent for publication
This study was approved by Québec Heart and Lung Institute Research Ethics Committee (protocol n° 2015-2466, 21160 and 21181, MP-10-2015-2489). All animal procedures were approved by McMaster University Animal Ethics Review Board (AREB, ref# 200103) and Institutional Animal Care and Use Committee at the University Health Network (UHN, ref# 5884.16) in accordance with the Canadian Council on Animal Care guidelines. Participants gave informed consent to participate in the study before taking part.
We are thankful to Mélissa Pelletier and Mélanie Nadeau for technical assistance with human data and samples, and to Nicola Henriquez for technical assistance with mass spectrometry.
Twitter @fernando_anhe, @BeatriceSY_Choi, @TKTLam, @SchertzerLab
Contributors FFA, JS, AM, TKTL and AT derived the hypothesis and researched the data. FFA conducted experiments, analysed the data and wrote the manuscript. SZ and S-YZ conducted experiments and analysed the data. BS-YC and NGB conducted experiments. CYC and KPF helped with experiments. LB performed surgeries. JS, AM and TKTL edited the manuscript. All authors contributed with data discussion and approved the manuscript prior to its submission. JS is the guarantor.
Funding This study was supported by a team grant from the Canadian Institutes of Health Research (CIHR) on bariatric care (TB2-138776), an Investigator-initiated study grant from Johnson & Johnson Medical Companies (Grant ETH-14-610) and a CIHR Canadian Microbiome Initiative 2 (CMI2) team grant (MRT-168045).
Disclaimer Funding sources for the trial had no role in the design, conduct or management of the study, in data collection, analysis or interpretation of data, or in the preparation of the present manuscript and decision to publish.
Competing interests FFA and S-YZ have Canadian Institutes of Health Research (CIHR) postdoctoral fellowships. AT and LB are recipients of research grant support from Johnson & Johnson Medical Companies, Bodynov and Medtronic for studies on bariatric surgery and the Research Chair in Bariatric and Metabolic Surgery at IUCPQ and Laval University. TKTL holds a Canada Research Chair in Diabetes and Obesity and a JK. McIvor endowed chair in Diabetes Research. JS holds a Canada Research Chair in Metabolic Inflammation. AM was supported by a CIHR/Pfizer research Chair in the pathogenesis of insulin resistance and cardiovascular diseases. JS is the guarantor of the study and, as such, assumes full responsability for the work and conduct of the study.
Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the 'Methods' section for further details.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.